CNTA

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

Retrieved on: 
Monday, November 13, 2023
Safety, Haemophilia, APC, ASH, Narcolepsy, CNTA, Administration, Patient, Investment, Sleep, Part, Neoplasm, OX2R, Trial of the century, Development, Congress, Society, Volunteering, World Sleep Day, Rare-earth element, Pharmaceutical industry, Palladium, Cryptocurrency, IND

Data from Part 5 of the ongoing Phase 2a study accepted for poster presentation at ASH on December 10, 2023.

Key Points: 
  • Data from Part 5 of the ongoing Phase 2a study accepted for poster presentation at ASH on December 10, 2023.
  • Research & Development Expenses: $28.2 million for the third quarter ended September 30, 2023, compared to $36.7 million for the third quarter ended September 30, 2022.
  • General & Administrative Expenses: $12.0 million for the third quarter ended September 30, 2023, compared to $12.3 million for the third quarter ended September 30, 2022.
  • Net Loss Attributable to Ordinary Shareholders: $38.6 million for the third quarter ended September 30, 2023, compared to $53.9 million for the third quarter ended September 30, 2022.

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Fibrinolysis, Person, Policy, Haemophilia, Serpin, Society, ASH, Pharmacokinetics, Male, APC, 52 Weeks Make A Year, Part, PWH, Safety, CNTA, Pharmaceutical industry

SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.

Key Points: 
  • SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
  • The Phase 2a study (AP-0101) is a first-in-human open-label multicenter study to investigate the safety, tolerability, pharmacokinetics and efficacy of subcutaneous doses of SerpinPC in male participants with severe hemophilia.
  • The Company has reported results from Parts 1-4, with results from Parts 3 and 4 shared during an oral presentation at ASH on December 10, 2022 .
  • Centessa plans to make the poster available at https://investors.centessa.com/events-presentations after the session concludes and in accordance with ASH’s embargo policy.

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

Retrieved on: 
Tuesday, October 31, 2023
Haemophilia, APC, Safety, Adolescence, Ageing, Patient, CNTA, Development, Pharmaceutical industry

BOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors.

Key Points: 
  • BOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors.
  • The Company began dosing subjects in the registrational PRESent-2 study for the treatment of hemophilia B without inhibitors in July 2023.
  • SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia B, with or without inhibitors.
  • Subjects must have undergone a minimum period of prospective observation (at least 12 weeks) under their current therapy before switching to SerpinPC treatment.

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, October 30, 2023
Patient, CNTA, Pharmaceutical industry, Online shopping

BOSTON and LONDON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Key Points: 
  • BOSTON and LONDON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
    Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations .

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Retrieved on: 
Wednesday, October 25, 2023
IH, BRT, Wakefulness, Sleep, Cataplexy, IND, NT2, Human, Congress, Narcolepsy, Electromyography, DTA, Idiopathic hypersomnia, OX2R, OX1R, PK, EC50, EMG, EEG, CHO, Patient, CNTA, Pharmaceutical industry, Aroma compound, Surat Bus Rapid Transit System, NT1

BOSTON and LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced a robust set of new preclinical data from in vivo and in vitro studies of its investigational, novel orexin receptor 2 (OX2R) agonist, ORX750, that support its potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders.

Key Points: 
  • “The preclinical data showed ORX750 achieved maximal wake times and suppressed cataplexy at 0.1 mg/kg, the lowest oral dose tested in the DTA mouse model.
  • Notably, this activity was observed in both the DTA and Atax mouse models that recapitulate NT1 symptoms in humans.
  • Fluorescent imaging plate reader (FLIPR) assay with Chinese hamster ovary (CHO) cells stably expressing recombinant human OX1R or OX2R; OXA EC50 at hOX2R = 0.035 nM.
  • As measured by electroencephalogram (EEG) and electromyogram (EMG) with concurrent video in DTA and Atax mouse models.

Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

Retrieved on: 
Tuesday, October 3, 2023
Data management, DevOps, BS, GSK plc, Drug development, Senior, Hematology, Drug, CNTA, Narcolepsy, Oncology, Merck & Co., Takeda Oncology, Medical director, MD, Patient, Haemophilia, Internal medicine, Catholic University College, Kensington, Merck, Cornell University, Society, Pharmaceutical industry, Nursing

“April has an impressive track record in global clinical trial strategy and execution across all stages of drug development.

Key Points: 
  • “April has an impressive track record in global clinical trial strategy and execution across all stages of drug development.
  • Prior to joining Centessa, Ms. Dovholuk was Senior Vice President, Clinical Development Operations at Replimune where she led teams in clinical operations, data management, process improvement and CRO management.
  • She most recently served as Senior Vice President, Clinical Development and Operations at Mersana Therapeutics Inc.
  • Previously, Dr. Im was Clinical Development Lead and Senior Medical Director at Tesaro Inc., an oncology-focused company that was later acquired by GlaxoSmithKline plc.

Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Thursday, August 31, 2023
Morgan Stanley, Morgan, CNTA, Patient, Conference, Pharmaceutical industry, Broadcasting

BOSTON and LONDON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, including a fireside chat on Tuesday, September 12, 2023 at 4:15 p.m.

Key Points: 
  • BOSTON and LONDON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, including a fireside chat on Tuesday, September 12, 2023 at 4:15 p.m.
  • ET.
  • The live webcast of this event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations .

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

Retrieved on: 
Wednesday, August 23, 2023
Congress, CNTA, Narcolepsy, Sleep, MD, Patient, Doctor of Philosophy, OX2R, Pharmaceutical industry

ORX750 is an orally administered, selective orexin receptor 2 (OX2R) agonist in preclinical development for the treatment of narcolepsy and other sleep disorders.

Key Points: 
  • ORX750 is an orally administered, selective orexin receptor 2 (OX2R) agonist in preclinical development for the treatment of narcolepsy and other sleep disorders.
  • In addition, Sarah Wurts Black, PhD, Head of Biology for Centessa’s orexin program, will co-chair a symposium at the Congress focused on the development of orexin receptor agonists.
  • Details of the presentation are as follows:
    Additional information about the World Sleep Congress is available at https://worldsleepcongress.com/program .
  • Centessa plans to make its presentation available on the Centessa website at https://investors.centessa.com/events-presentations after the presentations conclude.

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

Retrieved on: 
Monday, August 14, 2023
Narcolepsy, Investment, CD3, Neoplasm, CNTA, Haemophilia, Fast Track, Toxicity, Part, Person, Trial of the century, Congress, Development, ATM, Patient, Administration, OX2R, APC, FDA, Sleep, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Palladium, Pharmaceutical industry, Vaccine, Cryptocurrency

Research & Development Expenses: $33.7 million for the second quarter ended June 30, 2023, compared to $53.7 million for the second quarter ended June 30, 2022.

Key Points: 
  • Research & Development Expenses: $33.7 million for the second quarter ended June 30, 2023, compared to $53.7 million for the second quarter ended June 30, 2022.
  • General & Administrative Expenses: $13.3 million for the second quarter ended June 30, 2023, compared to $14.8 million the second quarter ended June 30, 2022.
  • Net Loss Attributable to Ordinary Shareholders: $24.9 million for the second quarter ended June 30, 2023, compared to $64.7 million for the second quarter ended June 30, 2022.
  • The net loss for the second quarter of 2023 included a tax benefit of $24.1 million, which primarily relates to a release of a valuation allowance on certain U.S. deferred tax assets in the quarter.

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

Retrieved on: 
Monday, July 10, 2023
Adolescence, Development, Ageing, APC, CNTA, Patient, Haemophilia, Safety, Person, Pharmaceutical industry

SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia B, with or without inhibitors.

Key Points: 
  • SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia B, with or without inhibitors.
  • “There remains a significant global need for new treatment options for persons with hemophilia B,” said Antoine Yver MD MSc, Chairman of Development of Centessa.
  • We are excited to be evaluating the potential of SerpinPC’s novel mechanism of action in the registrational PRESent-2 study.
  • The Company expects to begin dosing in its registrational PRESent-3 (AP-0103) study for subjects with hemophilia B with inhibitors this year.